NCT03913949 is a Phase 1 clinical trial of APG-2575 in Chronic Lymphocytic Leukemia, sponsored by Ascentage Pharma Group Inc..

Who is sponsoring NCT03913949?

NCT03913949 is sponsored by Ascentage Pharma Group Inc..

What drugs are being tested in NCT03913949?

Interventions in NCT03913949: APG-2575.

What condition does NCT03913949 study?

NCT03913949 studies Chronic Lymphocytic Leukemia, Non Hodgkin Lymphoma.

Is NCT03913949 still recruiting?

NCT03913949 is currently active, enrolled. Last updated 16 April 2025.

Last reviewed 2025-04-16 · How we verify

NCT03913949

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study to Evaluate the Safety,PK and PD of APG-2575 in Patients With Hematologic Malignancies

Active, enrolled Phase 1 Last updated 16 April 2025

What this trial tests

Phase 1 trial testing APG-2575 in Chronic Lymphocytic Leukemia in 74 participants. Participants enrolled and being followed up; not accepting new ones.

Timeline

3 June 2019

Primary endpoint
20 October 2024

31 December 2025

Quick facts

Lead sponsor	Ascentage Pharma Group Inc.
Phase	Phase 1
Status	Active, enrolled
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	74
Start date	3 June 2019
Primary completion	20 October 2024
Estimated completion	31 December 2025
Sites	5 locations across China

Drugs / interventions tested

APG-2575 — full drug profile →

Conditions studied

Chronic Lymphocytic Leukemia — all drugs for Chronic Lymphocytic Leukemia →
Non Hodgkin Lymphoma — all drugs for Non Hodgkin Lymphoma →

Sponsor

Ascentage Pharma Group Inc. — full company profile →

Who can join

18 and older, any sex, with Chronic Lymphocytic Leukemia or Non Hodgkin Lymphoma. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The purpose of this study is to assess the safety, tolerability, pharmacokinetic and pharmacodynamic properties of APG-2575 in patients with relapse or refractory chronic lymphocytic leukemia and non-hodgkin's lymphoma.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Targeting apoptosis in cancer therapy.
Carneiro BA, El-Deiry WS. · · 2020 · cited 1823× · PMID 32203277 · DOI 10.1038/s41571-020-0341-y
Apoptosis: A Comprehensive Overview of Signaling Pathways, Morphological Changes, and Physiological Significance and Therapeutic Implications.
Mustafa M, Ahmad R, Tantry IQ, Ahmad W, et al · · 2024 · cited 264× · PMID 39594587 · DOI 10.3390/cells13221838
Mitochondria-associated programmed cell death as a therapeutic target for age-related disease.
Nguyen TT, Wei S, Nguyen TH, Jo Y, et al · · 2023 · cited 221× · PMID 37612409 · DOI 10.1038/s12276-023-01046-5
Chronic lymphocytic leukemia in China.
Gale RP. · · 2022 · cited 17× · PMID 34636775 · DOI 10.1097/cm9.0000000000001811
Restoring Apoptosis with BH3 Mimetics in Mature B-Cell Malignancies.
Jullien M, Gomez-Bougie P, Chiron D, Touzeau C. · · 2020 · cited 13× · PMID 32183335 · DOI 10.3390/cells9030717
Current Status of Novel Agents for the Treatment of B Cell Malignancies: What's Coming Next?
Tannoury M, Garnier D, Susin SA, Bauvois B. · · 2022 · cited 10× · PMID 36551511 · DOI 10.3390/cancers14246026
Evaluating zanubrutinib for the treatment of adults with chronic lymphocytic leukemia or small lymphocytic lymphoma.
Javidi-Sharifi N, Brown JR. · · 2024 · cited 2× · PMID 38784995 · DOI 10.1080/17474086.2024.2356257
Epigenetic and post-translational regulatory networks of ferroptosis in the tumor immune microenvironment.
Du L, Zhang Y, Luo J, He C, et al · · 2026 · cited 1× · PMID 41588554 · DOI 10.1186/s40164-025-00737-1

Verify or expand the search:

Other trials of APG-2575

Trials testing the same drug.

NCT05701306 — APG-115 Alone or in Combination With APG-2575 in Children With Recurrent or Refractory Neuroblastoma or Solid Tumors · Phase 1 · recruiting
NCT04946864 — A Study to Investigate the Safety, Tolerability, of APG-2575 as a Single Agent or in Combination for Breast Cancer · Phase 1, PHASE2 · suspended
NCT04496349 — A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL · Phase 2 · recruiting
NCT03537482 — APG-2575 Study of Safety, Tolerability ,PK/PD in Patients With Hematologic Malignancies · EARLY_PHASE1 · recruiting

Other recruiting trials for Chronic Lymphocytic Leukemia

Currently open trials in the same condition.

NCT07020533 — A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Pa · Phase 1 · recruiting
NCT06863402 — Nemtabrutinib and Pembrolizumab for the Treatment of Richter Transformation, Diffuse Large B-cell Lymphoma Subtype · Phase 2 · recruiting
NCT07218510 — Venetoclax and Obinutuzumab Followed by Epcoritamab for the Treatment of Untreated Chronic Lymphocytic Leukemia and Smal · Phase 2 · recruiting
NCT07288515 — Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in Belarus · recruiting
NCT07014917 — Intermittent Versus Continuous Venetoclax With Acalabrutinib for CLL/SLL · Phase 2 · recruiting

Other Ascentage Pharma Group Inc. trials

Trials by the same sponsor.

NCT07282093 — Pharmacokinetics of Olverembatinib in Participants With Hepatic Impairment · Phase 1 · recruiting
NCT06640361 — A Study of Olverembatinib in SDH-deficient GIST. · Phase 3 · recruiting
NCT06389292 — A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia · Phase 3 · recruiting
NCT06104566 — Global Trial in APG2575 for Patients With CLL/SLL · Phase 3 · recruiting
NCT06051409 — A Study of Olverembatinib in Patients With Newly Diagnosed Ph+ALL. · Phase 3 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03913949 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ascentage Pharma Group Inc.
Last refreshed: 16 April 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03913949.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing